Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
OBJECTIVE
To examine the ability of cyclin-dependent kinase inhibitor (CDKI) roscovitine (Rosco) to enhance the antitumor effects of conventional chemotherapeutic agents acting by different mechanisms against human colorectal cancer.


METHODS
Human colorectal cancer cells were treated, individually and in combination, with Rosco, taxol, 5-Fluorouracil (5-FU), doxorubicine or vinblastine. The antiproliferative effects and the type of interaction of Rosco with tested chemotherapeutic drugs were determined. Cell cycle alterations were investigated by fluorescence-activated cell sorter FACS analysis. Apoptosis was determined by DNA fragmentation assay.


RESULTS
Rosco inhibited the proliferation of tumor cells in a time- and dose-dependent manner. The efficacies of all tested chemotherapeutic drugs were markedly enhanced 3.0-8.42 multiply 10(3) and 130-5.28 multiply 10(3) fold in combination with 5 and 10 microg/mL Rosco, respectively. The combination of Rosco and chemotherapeutic drugs inhibited the growth of human colorectal cancer cells in an additive or synergistic fashion, and in a time and dose dependent manner. Rosco induced apoptosis and synergized with tested chemotherapeutic drugs to induce efficient apoptosis in human colorectal cancer cells. Sequential, inverted sequential and simultaneous treatment of cancer cells with combinations of chemotherapeutic drugs and Rosco arrested the growth of human colorectal cancer cells at various phases of the cell cycle as follows: Taxol/Rosco (G2/M- and S-phases), 5-FU/Rosco (S-phase), Dox/Rosco (S-phase) and Vinb/Rosco (G2/M- and S-phases).


CONCLUSIONS
Since the efficacy of many anticancer drugs depends on their ability to induce apoptotic cell death, modulation of this parameter by cell cycle inhibitors may provide a novel chemo-preventive and chemotherapeutic strategy for human colorectal cancer.
Abaza
Mohamed Salah I
MS
Molecular Biology Program, Department of Biological Sciences, Faculty of Science, Kuwait University, PO Box 5696, Safaat 13006, Kuwait. abaza@kuc01.kuniv.edu.kw
Bahman
Abdul-Majeed A
AM
Al-Attiyah
Rajaa J
RJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D053938:DNA Fragmentation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use*; D000077546:Roscovitine; D013997:Time Factors; D014747:Vinblastine / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011687:Purines; D000077546:Roscovitine; D014747:Vinblastine; D004317:Doxorubicin; D017239:Paclitaxel; D005472:Fluorouracil
Cancer Biol Ther. 2002 Jul-Aug;1(4):420-5
12432259
Expert Opin Investig Drugs. 2006 Jan;15(1):23-38
16370931
Cancer Res. 1999 Apr 15;59(8):1903-10
10213499
Eur J Cancer. 1997 Apr;33(4):566-74
9274436
Cancer Res. 2003 May 15;63(10):2513-7
12750274
EMBO J. 2004 Dec 8;23(24):4868-75
15549137
Oncogene. 2000 Jun 22;19(27):3059-68
10871858
Carcinogenesis. 2002 May;23(5):687-96
12016139
Int J Oncol. 2002 Jul;21(1):95-101
12063555
Curr Med Chem. 1999 Sep;6(9):859-75
10495356
Oncogene. 2001 Sep 20;20(42):5951-63
11593402
J Biol Chem. 1997 Oct 10;272(41):26056-61
9325343
Tumour Biol. 2003 Sep-Oct;24(5):241-57
15001837
Neuroreport. 1999 Aug 20;10(12):2563-7
10574370
Int J Cancer. 2001 Aug 15;93(4):481-8
11477551
J Cell Biol. 1994 Feb;124(4):619-26
8106557
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
10735013
Clin Cancer Res. 2005 Nov 15;11(22):8158-71
16299248
Eur J Biochem. 1997 Jan 15;243(1-2):527-36
9030781
Clin Exp Metastasis. 1998 Jan;16(1):50-61
9502077
Mol Cell Biol. 2001 Apr;21(8):2755-66
11283255
Oncogene. 1999 Dec 9;18(52):7409-22
10602500
Science. 1998 Jan 23;279(5350):509-14
9438836
J Biol Chem. 1997 Feb 21;272(8):5214-8
9030591
Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6
11685731
Br J Biomed Sci. 2001;58(4):226-9
11787998
Anticancer Res. 1998 Jan-Feb;18(1A):301-7
9568094
J Biol Chem. 1993 Jul 25;268(21):15868-77
8340412
Adv Cancer Res. 1996;68:67-108
8712071
Int J Cancer. 2003 Sep 10;106(4):486-95
12845642
Prog Cell Cycle Res. 1995;1:351-63
9552377
Exp Cell Res. 1998 Jul 10;242(1):92-9
9665806
Urol Oncol. 2001 May;6(3):111-115
11344001
Nature. 2004 Oct 21;431(7011):1011-7
15496928
Cancer Lett. 2002 Jun 6;180(1):7-12
11911964
Eur J Biochem. 1997 Jan 15;243(1-2):518-26
9030780
Chembiochem. 2002 Jul 2;3(7):596-603
12324993
Nat Med. 1997 Feb;3(2):231-4
9018245